Dyadic International, Inc. (DYAI)
| Market Cap | 27.93M -23.3% |
| Revenue (ttm) | 3.09M -11.6% |
| Net Income | -7.36M |
| EPS | -0.23 |
| Shares Out | 36.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 348,063 |
| Open | 0.7310 |
| Previous Close | 0.7450 |
| Day's Range | 0.7000 - 0.7900 |
| 52-Week Range | 0.6546 - 1.3460 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+291.39%) |
| Earnings Date | May 13, 2026 |
About DYAI
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research a... [Read more]
Financial Performance
In 2025, Dyadic International's revenue was $3.09 million, a decrease of -11.59% compared to the previous year's $3.50 million. Losses were -$7.36 million, 26.8% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price target is $3.0.
News
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co...
Dyadic International Earnings Call Transcript: Q4 2025
Transitioned to a commercial-stage biotech with new product launches and expanded partnerships, though 2025 revenue declined to $3.09M and net loss widened. Expecting revenue growth in 2026, with cash runway into 2027 and a focus on recurring revenue streams.
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product sales E...
Dyadic International enter distribution partnership with IBT Bioservices
Dyadic Applied BioSolutions entered into an original equipment manufacturer distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices. Through this collaboration, Dyadic-produ...
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-enginee...
Dyadic International Transcript: Life Sciences Virtual Investor Forum
Transitioning from R&D to commercial operations, the company has launched multiple products in life sciences, food, and bioindustrial markets, leveraging its C1 and Dapibus platforms. Strategic partnerships and direct sales are driving early revenues, with significant growth expected from late 2026 as more products and collaborations mature.
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co...
Dyadic International, Fermbox Bio launch of RNase-Free
Dyadic Applied BioSolutions and Fermbox Bio announced the commercial launch of animal-origin-free Recombinant DNase I. This represents the first commercialized product under the companies expanded col...
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company produc...
Dyadic International, Inzymes announce planned 2026 commercialization
Dyadic Applied BioSolutions announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successfu...
Dyadic International, Inzymes announce planned 2026 commercialization
Dyadic Applied BioSolutions announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successfu...
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milesto
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing p...
Dyadic International, Fermbox Bio expand strategic collaboration
Dyadic Applied BioSolutions announced a significant expansion of its collaboration with Fermbox Bio. This expanded partnership broadens the range of products, platforms, and commercial opportunities t...
Dyadic International establishes commercial partnership with Opes
Dyadic Applied BioSolutions has entered into a commercial agreement with Opes Diagnosticsto support the commercial launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and ...
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins
JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes ...
Dyadic International Transcript: IAccess Alpha Virtual MicroCap Conference
A commercial inflection point is underway, with multiple animal-free protein products launching across life sciences, food nutrition, and bio-industrial markets. Strategic partnerships, rapid product development, and a layered revenue model are expected to drive growth and achieve cash flow positivity at a $12 million run rate.
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins...
Dyadic International reports Q3 EPS (6c), consensus (4c)
Reports Q3 revenue $1.16M, consensus $1.12M. “During the third quarter, Dyadic completed its strategic pivot from a research and development-driven company to a commercially focused biotechnology solu...
Dyadic International Earnings Call Transcript: Q3 2025
Q3 2025 marked a pivotal shift to commercial operations, with first bulk protein sales, expanded product launches, and global partnerships. Revenue declined year-over-year, but cash position strengthened and product revenue growth is expected in late 2025 and 2026.
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations Advanced ...
Dyadic International, ERS Genomics announces CRISPR/Cas9 license
ERS Genomics and Dyadic International (DYAI) announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio. “Access to ERS Genomics’ foundational ...
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology com...
Dyadic International assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Dyadic International (DYAI) with a Buy rating and $3 price target The company produces recombinant proteins based on proprietary fung...
Dyadic International announces achievement of milestone payments
Dyadic International (DYAI) announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes in food and nutrition, alon...